Minnesota is currently home to 2069 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
NCT05634512
Recruiting
This is a prospective, observational multicenter study to collect blood from patients with mucopolysaccharidosis type IH undergoing laronidase therapy and a stem cell transplant. Sixteen patients will be enrolled over a 24 month period.
Gender:
ALL
Ages:
Between 0 years and 3 years
Trial Updated:
11/01/2024
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Hematopoietic Cell Transplantation, Mucopolysaccharidosis Type I
Register for Updates
RA-PRO PRAGMATIC TRIAL
NCT04692493
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Saint Paul Rheumatology, P.A., Eagan, Minnesota
Conditions: Rheumatoid Arthritis
Register for Updates
Auto Stem Cell Transplant for Lymphoma Patients
NCT03125642
Recruiting
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Gender:
ALL
Ages:
75 years and below
Trial Updated:
11/01/2024
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Register for Updates
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
NCT01962636
Recruiting
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).
Gender:
ALL
Ages:
55 years and below
Trial Updated:
11/01/2024
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
Register for Updates
Contingency Management for Opioid and Stimulant Use Disorders in Primary Care
NCT05288751
Recruiting
Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. When applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit substances and increased engagement in treatment programs. However, there is a need to translate CM treatment to primary care settings. This study will implement and assess a CM program for patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Opioid Use Disorder, Stimulant Use Disorder
Register for Updates
Serial Amnioinfusions As Regenerative Therapy for Pulmonary Hypoplasia
NCT03723564
Recruiting
Congenital lower urinary tract obstruction (LUTO) is a heterogeneous group of congenital anomalies that lead bladder outlet obstruction. If a complete obstruction is present, the perinatal mortality is estimated to be as high as 90% because of severe pulmonary hypoplasia due to the lack of amniotic fluid. Survivors have significant risk of renal impairment (90%) requiring dialysis or renal transplantation if no fetal intervention is performed. Renal agenesis is the congenital absence of one or... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/31/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Renal Failure Congenital, Congenital Renal Anomaly Nos, Renal Agenesis and Dysgenesis, Lower Urinary Tract Obstructive Syndrome
Register for Updates
Technical Development of Multi-Parametric Renocerebral MRI
NCT02831335
Recruiting
The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and functional MRI methods along with a battery of cognitive tests.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
10/31/2024
Locations: Center for Magnetic Resonance Research, Minneapolis, Minnesota
Conditions: Aging
Register for Updates
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708
Recruiting
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Register for Updates
A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
NCT05889988
Recruiting
Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Essentia Health Baxter Clinic, Baxter, Minnesota
Conditions: Breast Neoplasm
Register for Updates
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II
NCT05754450
Recruiting
The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
Gender:
ALL
Ages:
Between 6 months and 75 years
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leukocyte Adhesion Deficiency
Register for Updates
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II
NCT05462587
Recruiting
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Gender:
ALL
Ages:
Between 6 months and 75 years
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leukocyte Adhesion Deficiency
Register for Updates
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis
NCT04973137
Recruiting
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Light Chain (AL) Amyloidosis
Register for Updates